ReviewJournal of advanced research2026
Probiotics and triglyceride manipulation: potential implications for alleviating hypertriglyceridemia.
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07720232 (Effect of Bacillus Subtilis and Enterococcus Faecium Combination Therapy Combined With Conventional Lipid-Lowering Treatment on Triglyceride Levels in Patients With Hypertriglyceridemic Acute Pancreatitis), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Bacillus Subtilis and Enterococcus Faecium Combination Therapy Combined With Conventional Lipid-Lowering Treatment on Triglyceride Levels in Patients With Hypertriglyceridemic Acute Pancreatitis: A Prospective Randomized Controlled Trial
Who cites it
3 citing papers in PubMed.
- Gut microbial community structure, metabolic signature, and resistome in dyslipidemia: implications for cardiovascular disease management.Microbiology spectrum · 2026Article
- An uncertainty-driven gated feature selection network (UGFS-Net) for TG level prediction: linking high-altitude exposure to lipid metabolism disorder via elevated TG.Lipids in health and disease · 2025Article
- Microbial Interactions with Intestinal Lipid Digestion and Absorption: Emerging Targets for Metabolic Disorders.Research (Washington, D.C.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertriglyceridemia is one of the most prevalent lipid abnormalities encountered in clinical practice. Although many monogenic disorders causing severe hypertriglyceridemia have been identified, in most patients, triglyceride elevations result from a combination of multiple genetic variations with small effects and environmental factors. Common secondary causes include obesity, uncontrolled diabetes, alcohol abuse, high-fat foods, and the use of various commonly prescribed drugs. Notably, manipulating the gut microbiota through probiotic intervention may reduce triglyceride levels by targeting intestinal lipid absorption and host lipid metabolism. AIM OF REVIEW: This paper reviews recent animal and human studies on probiotic interventions, summarizing the mechanisms through which probiotics reduce triglyceride levels and exploring the potential of next-generation probiotics in alleviating hypertriglyceridemia. KEY SCIENTIFIC CONCEPTS OF REVIEW: To discuss the link between gut microbiota and hypertriglyceridemia and the next generation of probiotics with the potential to reduce hypertriglyceridemia. Meanwhile, we also elucidate the mechanisms through which probiotics and their metabolites, such as short-chain fatty acids and bile acids, mediate multiple pathways to reduce triglyceride levels. Finally, the challenges and prospects of the application of probiotics were prospected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.